KM Biologics to File COVID-19 Vaccine as Early as September, Chancing Emergency Approval

KM Biologics President Toshiaki Nagasato KM Biologics plans to file for Japan approval of its inactivated COVID-19 vaccine KD-414 for unvaccinated adults aged between 18 and 40 (a course of three doses) as early as September this year, President Toshiaki...read more